Pfiz­er short­ens come­back cam­paign for armed an­ti­body in­o­tuzum­ab, lands quick FDA re­view

Pfiz­er’s armed an­ti­body in­o­tuzum­ab ozogam­icin — held up as a top on­col­o­gy con­tender at the phar­ma gi­ant — is be­ing giv­en the red car­pet treat­ment at the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.